Form 483 Observations Are Not GMP Guidance, FDA Says
This article was originally published in The Pink Sheet Daily
Industry should not use observations from FDA-483 reports as good manufacturing practices guidance, CDER Office of Compliance Director David Horowitz said.
You may also be interested in...
GMP initiative report will include final guidance on process analytical technologies and aseptic processing, as well as draft guidance on the use of quality systems and computerized systems in clinical trials. The release will also contain "white paper" on prioritizing manufacturing sites for inspections.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states